StreetInsider.com News Articles

Eikon Therapeutics shares EIK1001 lung cancer trial data at ESMO

Mon, 26 Oct 2026 06:03:00 -0400

Eikon Therapeutics (Nasdaq: EIKN) presented updated data from its TeLuRide-005 trial at the 2026 European Society for Medical Oncology Congress in Madrid, Spain, showing clinical activity for EIK1001 combined with pembrolizumab and chemotherapy in first-line stage 4 non-small cell lung cancer (NSCLC).

Among the 65 efficacy-evaluable participants, the combination produced a 63.1% objective response rate (ORR) and an 89.2% disease control rate (DCR) at the October 1, 2026, efficacy data cutoff, with a median follow-up of 17.2 months. Responses were observed across all PD-L1 tumor proportion score subgroups.

In the squamous cohort of 29 participants, the ORR was 72.4% and the DCR

Eikon Therapeutics shares EIK1001 lung cancer trial data at ESMO

Mon, 26 Oct 2026 06:03:00 -0400

In the squamous cohort of 29 participants, the ORR was 72.4% and the DCR

Eikon Therapeutics shares EIK1001 lung cancer trial data at ESMO

Mon, 26 Oct 2026 06:03:00 -0400

In the squamous cohort of 29 participants, the ORR was 72.4% and the DCR

Form 8-K Eikon Therapeutics, Inc. For: Oct 26

Mon, 26 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261026/27230056.html

Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress

Mon, 26 Oct 2026 06:00:00 -0400

TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile supportive of systemic administration in an outpatient setting
With median follow-up of 12.7 months, objective response rate (ORR) for the squamous cohort was 72% and disease control rate (DCR) was 100%, with a median duration of response of 12.9 months and multiple participants continuing in active follow-up
TeLuRide-008, an ongoing adaptive Phase 2/3 trial of EIK1001 in NSCLC, actively enrolling, with a prespecified interim analysis for dose selection anticipated in 2H

Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress

Mon, 26 Oct 2026 06:00:00 -0400

TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile supportive of systemic administration in an outpatient setting
With median follow-up of 12.7 months, objective response rate (ORR) for the squamous cohort was 72% and disease control rate (DCR) was 100%, with a median duration of response of 12.9 months and multiple participants continuing in active follow-up
TeLuRide-008, an ongoing adaptive Phase 2/3 trial of EIK1001 in NSCLC, actively enrolling, with a prespecified interim analysis for dose selection anticipated in 2H

Form 8-K Eikon Therapeutics, Inc. For: Oct 23

Fri, 23 Oct 2026 09:15:00 -0400
si-local-file:///var/storage/secattach/20261023/27225773.html

Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress

Fri, 23 Oct 2026 09:15:00 -0400

Initial and updated cohort data from ongoing Phase 1/2 study of highly selective non-brain-penetrant PARP1 inhibitor EIK1003 continue to support potentially differentiated profile of EIK1003 in combination strategies within the PARP inhibitor landscape
Initial results from ongoing Phase 1/2 study of highly selective CNS-penetrant PARP1 inhibitor EIK1004 demonstrate a generally well-tolerated safety profile across multiple dose levels, with minimal Grade 3 or higher hematologic toxicities as of the safety data cutoff
Preliminary data for Werner (WRN) helicase inhibitor EIK1005 support continued development as monotherapy and in combination with pembrolizumab, with pharmacokinetic (PK) profile supporting weekly administration
Additional data

Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress

Fri, 23 Oct 2026 09:15:00 -0400

Initial and updated cohort data from ongoing Phase 1/2 study of highly selective non-brain-penetrant PARP1 inhibitor EIK1003 continue to support potentially differentiated profile of EIK1003 in combination strategies within the PARP inhibitor landscape
Initial results from ongoing Phase 1/2 study of highly selective CNS-penetrant PARP1 inhibitor EIK1004 demonstrate a generally well-tolerated safety profile across multiple dose levels, with minimal Grade 3 or higher hematologic toxicities as of the safety data cutoff
Preliminary data for Werner (WRN) helicase inhibitor EIK1005 support continued development as monotherapy and in combination with pembrolizumab, with pharmacokinetic (PK) profile supporting weekly administration
Additional data

Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress

Sun, 18 Oct 2026 18:05:00 -0400

Presentations to cover updates across Eikon’s clinical pipeline including:

Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and histology-appropriate chemotherapy in stage 4 non-small cell lung cancer (NSCLC)
Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumors
Initial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancer
Initial results from an ongoing Phase 1/2 study of EIK1004,

Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress

Sun, 18 Oct 2026 18:05:00 -0400

Presentations to cover updates across Eikon’s clinical pipeline including:

Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and histology-appropriate chemotherapy in stage 4 non-small cell lung cancer (NSCLC)
Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumors
Initial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancer
Initial results from an ongoing Phase 1/2 study of EIK1004,

H.C. Wainwright Starts Eikon Therapeutics Inc. (EIKN) at Buy

Fri, 16 Oct 2026 06:08:49 -0400

H.C. Wainwright analyst Sara Nik initiates coverage on Eikon Therapeutics Inc. (NASDAQ: EIKN) with a Buy rating and a price target of $23.00.
For an analyst ratings summary and ratings history on Eikon Therapeutics Inc. click here. For more ratings news on Eikon Therapeutics Inc. click here.
Shares of Eikon Therapeutics Inc. closed at $7.54 yesterday.

Eikon Therapeutics files IND for prostate cancer drug EIK1006

Thu, 15 Oct 2026 08:01:19 -0400

Eikon Therapeutics, Inc. (Nasdaq: EIKN) announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for EIK1006, a drug candidate for the treatment of advanced metastatic prostate cancer.
EIK1006 is an androgen receptor (AR) antagonist that the company states is structurally unrelated to currently available lutamide-class antagonists. According to the company, the candidate targets both wild-type androgen receptors and variants associated with resistance to existing prostate cancer therapies.
Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon, said the IND submission reflects the company's imaging platform, which he described as enabling

Eikon Therapeutics files IND for prostate cancer drug EIK1006

Thu, 15 Oct 2026 08:01:19 -0400

Eikon Therapeutics, Inc. (Nasdaq: EIKN) announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for EIK1006, a drug candidate for the treatment of advanced metastatic prostate cancer.
EIK1006 is an androgen receptor (AR) antagonist that the company states is structurally unrelated to currently available lutamide-class antagonists. According to the company, the candidate targets both wild-type androgen receptors and variants associated with resistance to existing prostate cancer therapies.
Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon, said the IND submission reflects the company's imaging platform, which he described as enabling

Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer

Thu, 15 Oct 2026 08:00:00 -0400

Internally-derived candidate targets wild-type androgen receptor and clinically relevant variants implicated in resistance to conventional prostate cancer therapies
MILLBRAE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer. EIK1006 is a novel androgen receptor (AR) antagonist that is structurally unrelated to currently available lutamide-class antagonists.

“The submission of an IND for EIK1006 demonstrates once again that

Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer

Thu, 15 Oct 2026 08:00:00 -0400

Internally-derived candidate targets wild-type androgen receptor and clinically relevant variants implicated in resistance to conventional prostate cancer therapies
MILLBRAE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer. EIK1006 is a novel androgen receptor (AR) antagonist that is structurally unrelated to currently available lutamide-class antagonists.

“The submission of an IND for EIK1006 demonstrates once again that

Form SCHEDULE 13G/A Eikon Therapeutics, Inc. Filed by: FMR LLC

Wed, 07 Oct 2026 11:47:00 -0400
si-local-file:///var/storage/secattach/20261007/27159979.html

Form SCHEDULE 13G/A Eikon Therapeutics, Inc. Filed by: Abu Dhabi Investment Authority

Fri, 02 Oct 2026 11:14:00 -0400
si-local-file:///var/storage/secattach/20261002/27140152.html

Eikon Therapeutics names new chief scientific officer from Bristol Myers Squibb

Thu, 03 Sep 2026 07:30:42 -0400

Eikon Therapeutics, Inc. (Nasdaq: EIKN) has appointed Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer, the company announced in a press release.

Dr. Chang joins Eikon from Bristol Myers Squibb, where he most recently served as Vice President and Head of Cardiovascular Discovery Biology and Translational Pharmacology. Before that role, he served as Head of Cardiovascular Research at Gilead Sciences and then as Vice President of Disease Biology at MyoKardia, where he worked on the characterization of mavacamten, a drug later approved for the treatment of hypertrophic cardiomyopathy.

Dr. Chang also held academic positions at Stanford University, where

Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer

Thu, 03 Sep 2026 07:30:00 -0400

MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ching-Pin (“CP”) Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer.

Dr. Chang is a physician-scientist and accomplished research leader with more than two decades of experience spanning academic medicine, foundational research, and drug discovery. He joins Eikon from Bristol Myers Squibb, where he most recently served as Vice President, Head of Cardiovascular Discovery Biology and Translational Pharmacology.

“CP

Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer

Thu, 03 Sep 2026 07:30:00 -0400

MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ching-Pin (“CP”) Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer.

Dr. Chang is a physician-scientist and accomplished research leader with more than two decades of experience spanning academic medicine, foundational research, and drug discovery. He joins Eikon from Bristol Myers Squibb, where he most recently served as Vice President, Head of Cardiovascular Discovery Biology and Translational Pharmacology.

“CP

Eikon Therapeutics to Participate in Investor Conferences in September 2026

Wed, 26 Aug 2026 07:30:00 -0400

MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor conferences taking place in September:

Event:12^th Annual Cantor Global Healthcare Conference
Location: New York, NY
Date & Time: September 10, 2026 at 2:10 pm ET
Format: Fireside Chat

Event: The Morgan Stanley 24th Annual Global Healthcare Conference
Location: New

Eikon Therapeutics to Participate in Investor Conferences in September 2026

Wed, 26 Aug 2026 07:30:00 -0400

MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor conferences taking place in September:

Event:12^th Annual Cantor Global Healthcare Conference
Location: New York, NY
Date & Time: September 10, 2026 at 2:10 pm ET
Format: Fireside Chat

Event: The Morgan Stanley 24th Annual Global Healthcare Conference
Location: New

Eikon Therapeutics (EIKN) Reiterated at Overweight by Cantor Fitzgerald

Fri, 21 Aug 2026 08:29:05 -0400

Cantor Fitzgerald analyst Imogen Mansfield reiterated an Overweight rating on Eikon Therapeutics Inc. (NASDAQ: EIKN).
The analyst commented, "EIKN is pursuing combinations for EIK1003 paclitaxel, carboplatin/ paclitaxel (both in multiple solid tumors), and abiraterone (in metastatic prostate cancer). EIK1004, EIKN's brain penetrant program, has monotherapy data upcoming at ESMO but EIKN plans to pursue a similar broad combination strategy. This asset has a particularly interesting opportunity in breast cancer, where BRCA mutant disease is at high risk of metastasizing to the brain."
For an analyst ratings summary and ratings history on Eikon Therapeutics Inc. click here. For more ratings news on

Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald

Tue, 18 Aug 2026 16:15:00 -0400

MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that its Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and featuring Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and physician scientist from the University of Texas MD Anderson Cancer Center.

Dr. Timothy A. Yap currently serves as Vice